Structure posts early oral obesity data, delays larger readout

Structure posts early oral obesity data, delays larger readout

Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. | Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks.

Recombinant Human EGF Protein, CF 236-EG-200: R&D Systems

NAD+ in COVID-19 and viral infections: Trends in Immunology

Alzheimer disease Nature Reviews Disease Primers

Nutrients, Free Full-Text

Oxadiazolopyridine Derivatives as Efficacious Mitochondrial Uncouplers in the Prevention of Diet-Induced Obesity

Use of the Historial Weight Trajectory to Guide an Obesity Focused Patient Encounter - Endotext - NCBI Bookshelf

Dopaminergic signalling limits suppressive activity and gut homing of regulatory T cells upon intestinal inflammation

Two Years into the COVID-19 Pandemic: Lessons Learned

IJMS, Free Full-Text

Structure tumbles as oral GLP-1 data underwhelm investors

Frontiers Maternal Immunization: Nature Meets Nurture

DNA, Free Full-Text

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials - The Lancet

Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor: Trends in Endocrinology & Metabolism

Nutrients, Free Full-Text